Pfizer to Supply Global Fund Up to 6 Million Paxlovid Treatment Courses
By Will Feuer
Pfizer Inc. said it has agreed to supply up to six million
treatment courses of Paxlovid, its oral treatment for Covid-19, to
the Global Fund for low-and-middle-income countries, based on
Pfizer's tiered pricing.
The Global Fund says it is a movement focused on defeating HIV,
tuberculosis and malaria. It raises and invests $4 billion a year
to fight the world's deadliest infectious diseases, according to
its website. The organization's Covid-19 response mechanism has
awarded $4.3 billion to 131 countries since April 2020 to mitigate
the impact of the pandemic on programs to fight HIV, TB and
malaria, its website says.
Pfizer said the Global Fund's Covid-19 response mechanism has
been the main channel for providing grant support to low- and
middle-income countries to purchase Covid tests, treatments and
personal protective equipment. The company said Paxlovid treatment
courses would be available for procurement through the program,
subject to local regulatory approval or authorization of the
Pfizer said it expects supply to be available starting this
year, with doses of Paxlovid offered based on the company's tiered
pricing approach, in which low- and lower-middle-income countries
will pay a not-for-profit price. The company didn't disclose other
financial details of the deal.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
September 22, 2022 07:23 ET (11:23 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
から 11 2022 まで 12 2022
から 12 2021 まで 12 2022